Brozzi Nicolas A, Cifuentes Renzo O, Saba Isabela C, Macon Conrad, Ghodsizad Ali, Andreopoulos Fotios, Loebe Matthias
Department of Surgery, Division of Thoracic Transplantation and Mechanical Circulatory Support, Miller School of Medicine, University of Miami, Miami, Florida, USA.
J Card Surg. 2020 Dec;35(12):3405-3408. doi: 10.1111/jocs.15074. Epub 2020 Oct 1.
Heart failure is an epidemic affecting over 6 million people in the United States. Eighty percent of all heart failure patients are older than 65 years of age. Heart transplant is the gold standard treatment for patients suffering advanced heart failure, but only 18.5% of patients receiving heart transplant in the United States are 65 years of age or older. Continuous-flow left ventricular assist devices are a safe and effective therapy for patients with advanced heart failure, and can be used to bridge patients to a heart transplant or to support patients long-term as destination therapy.
We sought to characterize long-term outcomes of elderly patients receiving continuous-flow left ventricular support in our program.
Elderly patients with advanced heart failure presented comparable operative results to those of younger patients. The rate of complications up to 6 years of support was low, and comparable to those of younger patients. An effective and safe alternative for patients whom are less likely to receive heart transplantation.
心力衰竭是一种流行病，在美国影响着超过600万人。所有心力衰竭患者中有80%年龄超过65岁。心脏移植是晚期心力衰竭患者的金标准治疗方法，但在美国接受心脏移植的患者中，只有18.5%的患者年龄在65岁及以上。连续流左心室辅助装置是晚期心力衰竭患者的一种安全有效的治疗方法，可用于将患者过渡到心脏移植或作为终末期治疗长期支持患者。
我们试图描述在我们的项目中接受连续流左心室支持的老年患者的长期结局。
晚期心力衰竭老年患者的手术结果与年轻患者相当。长达6年的支持期内并发症发生率较低，与年轻患者相当。对于不太可能接受心脏移植的患者来说，这是一种有效且安全的替代方法。
